Can a targeted drug boost standard therapy for a rare lymphoma?

NCT ID NCT04212013

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This phase 3 trial is testing whether adding the targeted drug ibrutinib to standard rituximab therapy can improve outcomes for people with untreated marginal zone lymphoma, a slow-growing blood cancer. Participants are randomly assigned to receive either ibrutinib plus rituximab or a placebo plus rituximab. The study aims to see if the combination leads to a higher rate of complete response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: a combination of the targeted drug ibrutinib and the antibody therapy rituximab
What this could lead to: If it works, this combination could offer a more effective first-line treatment for marginal zone lymphoma, potentially improving response rates and delaying disease progression.
What could go wrong: This is a relatively small phase 3 trial, and the benefit of adding ibrutinib to rituximab is not yet proven. Ibrutinib can cause side effects like bleeding, infection, and heart rhythm problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MARGINAL ZONE LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MARGINAL ZONE LYMPHOMA

Contacts and locations

Show contact details

Locations

George Washington Cancer Center

Washington D.C., District of Columbia, 20037, United States
Mayo Clinic Cancer Center

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Memorial Sloan Kettering Commack

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Nassau

Uniondale, New York, 11553, United States
Memorial Sloan Kettering Westchester

Harrison, New York, 10604, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.